Lasinavir

Lasinavir
Names
	Systematic IUPAC name tert-Butyl (3S,4S,6R,9S)-13-benzyl-12-hydroxy-6,9-dioxo-7-(propan-2-yl)-10-[(2,3,4-trimethoxyphenyl)methyl]-2-oxa-5,8,14-triazapentadecan-15-oate
Identifiers
CAS Number	175385-62-3 ;
3D model (JSmol)	Interactive image;
ChemSpider	408297 ;
PubChem CID	464372;
UNII	0QGV8237I3 ;
	InChI InChI=1S/C35H53N3O9/c1-22(2)29(33(41)36-17-18-43-6)38-32(40)25(20-24-15-16-28(44-7)31(46-9)30(24)45-8)21-27(39)26(19-23-13-11-10-12-14-23)37-34(42)47-35(3,4)5/h10-16,22,25-27,29,39H,17-21H2,1-9H3,(H,36,41)(H,37,42)(H,38,40)/t25-,26+,27+,29+/m1/s1 Key: BEUUJDAEPJZWHM-COROXYKFSA-N;
	SMILES CC(C)[C@@H](C(=O)NCCOC)NC(=O)[C@H](CC1=C(C(=C(C=C1)OC)OC)OC)C[C@@H]([C@H](CC2=CC=CC=C2)NC(=O)OC(C)(C)C)O;
Properties
Chemical formula	C35H53N3O9
Molar mass	659.81 g/mol
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). (what is ?) Infobox references

Lasinavir (INN,^[1] previously known as BMS-234475 and CGP-61755) is an experimental peptidomimetic protease inhibitor researched by Novartis and Bristol-Myers Squibb as a treatment for HIV infection. It was originally discovered by Novartis at Basel (Switzerland).^[2] Its investigation was terminated after Phase I on October 09, 2002.^[3]

References

^ "International Nonproprietary Names for Pharmaceutical Substances (INN). RECOMMENDED International Nonproprietary Names (Rec. INN): List 38" (PDF). WHO Drug Information. 11 (3). World Health Organization: 170. 1997. Retrieved 25 November 2015.
^ B2 US patent 7348345 B2, James Patrick Dunn, Steven Swallow, Zachary Kevin Sweeney, "Nonnucleoside reverse transcriptase inhibitors", issued 2008-08-02
^ "Drug Profile: Lasinavir". AdisInsight. Adis International Ltd, part of Springer Science+Business Media. Retrieved 25 November 2015.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.